International Alliance for
Biological Standardization

Globally Harmonized Specifications: Current State and Future Opportunities
September 14-15, 2022
Kunstmuseum, Basel, Switzerland

Xianghong Emily Jing

Associate Director of Scientific Coordination

Office of Biotechnology Products, CDER, FDA
10903 New Hampshire Ave
Silver Spring, MD 20993

Tel: +1-240-402-9607

E-mail: Emily.jing@fda.hhs.gov

Dr. Emily Jing is currently the Associate Director of Scientific Coordination in Office of Biotechnology Products at CDER/FDA. She oversees cross-cutting office activities that include regulatory knowledge management, labeling assessments, and workload management. She joined the FDA in the Office of Vaccine Research and Review (OVRR) at CBER in 2009. She participated in a broad WHO collaboration to select influenza vaccine strains and served as the primary product quality assessor for the first cell-based influenza vaccine Biologics License Application (BLA). Emily joined Office of Biotechnology products at CDER/FDA in 2014 and has overseen the product quality reviews for numerous investigational New Drug Applications (INDs), Biological Product License Applications (BLAs), biosimilars, and deemed biologics. She has participated multiple Pre-licensure Inspections as CMC expert. During the COVID-19 pandemic, Emily led the CMC assessment of IND and EUA submissions for COVID 19, and supported development of other COVID 19 therapeutics as well as potency assay guidance for such products.